Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer |
| |
| Authors: | Seungtaek Lim Soohyeon Lee Jungwoo Han Byeong-Woo Park SeungIl Kim Seho Park Joo-Hang Kim Hye Jin Choi Joohyuk Sohn |
| |
| Affiliation: | 1. Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea;2. Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea;3. Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea |
| |
| Abstract: | ObjectiveWe investigated the efficacy of maintenance hormone therapy (MHT), which was given to hormone positive metastatic breast cancer (MBC) patients in non-progression status to the previous chemotherapy.MethodsThis study retrospectively analyzed 76 MBC patients who had been treated with MHT from 2006 to 2010 at a single institute.ResultsFor the 76 patients reviewed, the median progression free survival (PFS) to MHT was 14.4 months (95% CI, 11.6–17.3). Prolonged PFS was associated with less previous palliative chemotherapy, fewer metastatic sites, and the absence of visceral metastasis in univariate analysis. Multivariate analysis showed that only the number of previous palliative chemotherapy (HR 1.73, 95% CI, 1.00–2.98; P = 0.04) remained as a significant variable. MHT was generally well tolerated.ConclusionsMHT showed considerable efficacy and tolerability in this study. Further randomized prospective study is warranted. |
| |
| Keywords: | Breast cancer Hormone therapy Maintenance MBC" },{" #name" :" keyword" ," $" :{" id" :" kwrd0030" }," $$" :[{" #name" :" text" ," _" :" metastatic breast cancer ER" },{" #name" :" keyword" ," $" :{" id" :" kwrd0040" }," $$" :[{" #name" :" text" ," _" :" estrogen receptor PR" },{" #name" :" keyword" ," $" :{" id" :" kwrd0050" }," $$" :[{" #name" :" text" ," _" :" progesterone receptor PFS" },{" #name" :" keyword" ," $" :{" id" :" kwrd0060" }," $$" :[{" #name" :" text" ," _" :" progression free survival MHT" },{" #name" :" keyword" ," $" :{" id" :" kwrd0070" }," $$" :[{" #name" :" text" ," _" :" maintenance hormone therapy OS" },{" #name" :" keyword" ," $" :{" id" :" kwrd0080" }," $$" :[{" #name" :" text" ," _" :" overall survival RECIST" },{" #name" :" keyword" ," $" :{" id" :" kwrd0110" }," $$" :[{" #name" :" text" ," _" :" response evaluation criteria in solid tumors MPA" },{" #name" :" keyword" ," $" :{" id" :" kwrd0135x" }," $$" :[{" #name" :" text" ," _" :" medroxyprogesteron acetate |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
